Results 271 to 280 of about 75,327 (314)
Some of the next articles are maybe not open access.

Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.

Blood, 2000
Human immunodeficiency virus-1 (HIV-1) infection has been shown to result in up-regulation of the urokinase-type plasminogen activator receptor (uPAR/CD87) on leukocytes in vitro and in vivo. The objective of this study was to investigate whether this up-
N. Sidenius   +6 more
semanticscholar   +1 more source

Interconversion of Active and Inactive Conformations of Urokinase-Type Plasminogen Activator

Biochemistry, 2012
The catalytic activity of serine proteases depends on a salt-bridge between the amino group of residue 16 and the side chain of Asp194. The salt-bridge stabilizes the oxyanion hole and the S1 specificity pocket of the protease. Some serine proteases exist in only partially active forms, in which the amino group of residue 16 is exposed to the solvent ...
Masood Hosseini   +9 more
openaire   +4 more sources

Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.

Current pharmaceutical design, 2003
Degradation of the extracellular matrix plays an important role in a number of normal and pathological conditions involving active tissue remodeling such as postlactational mammary gland involution, wound healing and tumor invasion and metastasis.
M. Ploug
semanticscholar   +1 more source

Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator.

European Journal of Biochemistry, 1985
Controlled extracellular proteolysis is catalyzed in part by the secretion of plasminogen activators. As a step in the study of the expression of these enzymes in mouse tissues, we have isolated five cDNAs encoding the mouse urokinase-type plasminogen ...
D. Belin   +7 more
semanticscholar   +1 more source

Inhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator

Current Pharmaceutical Design, 2002
Human urokinase-type plasminogen activator (uPA or uPA) has been implicated in the regulation and control of basement membrane and interstitial protein degradation. Since Urokinase plays a role in tissue remodeling, it may be responsible, in part, for the disease progression of cancer.
Vicki L. Nienaber   +2 more
openaire   +3 more sources

Identification of a novel inhibitor of urokinase-type plasminogen activator

Molecular Cancer Therapeutics, 2007
AbstractUrokinase-type plasminogen activator (uPA), a highly restricted serine protease, plays an important role in the regulation of diverse physiologic and pathologic processes. Strong clinical and experimental evidence has shown that elevated uPA expression is associated with cancer progression, metastasis, and shortened survival in patients.
Ming Zhu   +8 more
openaire   +3 more sources

Modulators of the urokinase-type plasminogen activation system for cancer

Expert Opinion on Investigational Drugs, 2010
The serine protease urokinase-type plasminogen activator (uPA) and its receptor uPAR as well as two specific inhibitors, the plasminogen activator inhibitor type-1 (PAI-1) and type-2 (PAI-2), are involved in the control of extracellular matrix turnover and tumor growth.
Alexander Marx   +3 more
openaire   +3 more sources

Bovine embryos produce a urokinase‐type plasminogen activator

Molecular Reproduction and Development, 1992
AbstractThe type of plasminogen activator (PA) secreted by bovine embryos was identified. Day 12–14 embryos were collected from estrus‐synchronized, superovulated, and naturally mated crossbred beef cows. Embryos were left intact (E) or microdissected into component embryonic discs (ED) and trophoblastic vesicles (TV).
A. R. Menino, Debra A. Berg
openaire   +3 more sources

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Journal of Clinical Oncology, 2002
PURPOSE A strong prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor and plasminogen activator inhibitor type 1 (PAI-1) as individual factors is well established in breast cancer.
N. Harbeck, R. Kates, M. Schmitt
semanticscholar   +1 more source

Urokinase-type plasminogen activator in human eccrine sweat

British Journal of Dermatology, 1993
The presence of urokinase-type plasminogen activator (uPA) in human eccrine sweat has not been reported previously. Clean sweat was obtained from the upper trunk and arms of subjects which had been painted with white petrolatum to minimize epidermal contamination. Sweat was concentrated x 50 by ultrafiltration, and its PA activity determined by the two-
Kenzo Sato, T. Hibino, T. Takemura
openaire   +3 more sources

Home - About - Disclaimer - Privacy